Results from EMBRACE Phase 2a study of emapalumab in interferon-gamma-driven sepsis presented at ISICEM
Primary endpoint: improvement in organ function observed in 60% of patients receiving high-dose emap...
Publisher
Sweden
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Primary endpoint: improvement in organ function observed in 60% of patients receiving high-dose emap...
Source route
Continue on sobi.com
Leave the platform to read the original full article on the publisher site.
Source: Swedish Orphan Biovitrum
Scope: Industry
Related coverage
More related coverage
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announ...
Subscribe to Press release email alerts
Sign up for BMY email alerts and receive timely updates on press releases.